STOCK TITAN

TransMedics to Report First Quarter 2022 Financial Results on May 3, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

TransMedics Group, Inc. (Nasdaq: TMDX), a leader in organ transplant technology, will announce its first-quarter 2022 financial results on May 3, 2022, after market close. A conference call to discuss these results will take place at 5:00 p.m. ET. Investors can access the call by dialing (844) 200-6205 domestically or (929) 526-1599 internationally, using Conference ID: 215877. The company aims to enhance organ preservation and assessment for transplants, addressing vital needs in heart, lung, and liver failure treatments.

Positive
  • Leading position in portable organ perfusion technology.
  • Focus on increasing organ utilization for transplant needs.
Negative
  • None.

ANDOVER, Mass., April 19, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter of 2022 after market close on Tuesday, May 3, 2022. The TransMedics management team will host a corresponding conference call beginning at 5:00 p.m. ET / 2:00 p.m. PT.

Investors interested in listening to the conference call may do so by dialing (844) 200-6205 for domestic callers or (929) 526-1599 for international callers, followed by Conference ID: 215877. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/

About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:
Brian Johnston
332-895-3222
Investors@transmedics.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-report-first-quarter-2022-financial-results-on-may-3-2022-301528544.html

SOURCE TransMedics Group, Inc.

FAQ

When will TransMedics report first-quarter 2022 financial results?

TransMedics will report its first-quarter 2022 financial results on May 3, 2022.

What time is the TransMedics conference call scheduled?

The conference call is scheduled for 5:00 p.m. ET on May 3, 2022.

How can I listen to the TransMedics earnings call?

Investors can listen to the call by dialing (844) 200-6205 for domestic calls or (929) 526-1599 for international calls.

What is the purpose of TransMedics' technology?

TransMedics' technology aims to improve organ quality and increase the viability of donor organs for transplantation.

TransMedics Group, Inc.

NASDAQ:TMDX

TMDX Rankings

TMDX Latest News

TMDX Stock Data

2.03B
32.48M
3.18%
112.86%
26.74%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
ANDOVER